PARP1 and breast cancer: Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors (PARPi) leverage deficiencies associated with homologous repair that are conferred by tumor mutations in BRCA-related genes, and have proven efficacy in breast cancer.